

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083

Status	RECRUITING
Phase	Phase 3
Sponsor	Boehringer Ingelheim
Enrollment	286 participants

Key Eligibility Criteria

Inclusion (9)

- Male or female participants e12 years old on the day of signing informed consent/assent (Visit 1)
- Weight of e40 kg at the screening visit (Visit 1)
- Body mass index (BMI) of d40 kg/m² at the screening visit (Visit 1)
- Participants with a diagnosis prior to the screening visit (Visit 1) of either:
- Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based on Investigator's judgement) OR ... and 4 more (see full listing online)

Exclusion (4)

- Known monogenic or syndromic causes of FSGS (with the exception of TRPC6 gain-of-function gene mutations)
- Clinical or histologic evidence of secondary maladaptive or toxic forms of FSGS (based on Investigator's judgement)
- FSGS of undetermined cause (FSGS-UC) with a diagnosis prior to the screening visit (Visit 1) (based on Investigator's judgement)
- A history of organ transplantation or planned organ transplantation during the course of the trial

Locations (251 total)

Alabama Kidney Research, Alabaster, Alabama, United States
Apogee Clinical Research, Huntsville, Alabama, United States
Southwest Kidney Institute, Surprise, Arizona, United States
... and 248 more locations

<https://clinicaltrials.gov/study/NCT07220083>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.